文献速递性腺与生殖内分泌

患者管理:多毛症

Approach to the Patient: Hirsutism.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

多毛症影响全球约10%女性,经济与生活质量负担显著。该文综述多毛症的病理生理、改良Ferriman-Gallwey(mFG)评分诊断(通常mFG>4~6,阈值随种族略有差异)及常见病因,并强调治疗需结合症状严重度、生育目标与病因,采用药物与物理脱毛联合及共享决策。

要点

  • 多毛症通常以改良Ferriman-Gallwey评分评估9个部位终毛,mFG>4~6提示多毛,具体阈值随种族略有差异。
  • 多毛症女性中80%~90%为多囊卵巢综合征,5%~10%为特发性多毛,1%~10%为21-羟化酶缺陷非经典型肾上腺增生。
  • 治疗选择取决于症状严重度、生育目标和病因,最有效策略为药物与物理脱毛联合,并以共享决策为关键驱动。

核心结论

  • 多毛症影响全球约10%女性,带来显著经济与生活质量影响。
  • 临床医生不应低估多毛症给患者带来的痛苦程度。
  • 因多毛主诉就诊的女性无论体检可见程度如何,均应评估潜在病因。
  • 最有效的治疗策略为药物与物理脱毛方法联合,共享决策是关键驱动。

研究设计与样本

  • 本文为《临床内分泌与代谢杂志》患者管理综述,未报告系统检索范围与样本量。

主要发现

  • 面部与躯体终毛呈男性型生长由循环雄激素及组织雄激素受体、5α-还原酶、3α-和17β-羟类固醇脱氢酶、鸟氨酸脱羧酶含量等因素决定。
  • 多毛症通常采用改良Ferriman-Gallwey视觉量表评估9个部位(上唇、下巴、胸部、上背和下背、上腹和下腹、上臂、大腿)的终毛量。
  • 多毛症诊断阈值随种族略有差异,通常定义为mFG评分大于4~6。
  • 多毛症女性中80%~90%为多囊卵巢综合征,5%~10%为特发性多毛,1%~10%(取决于种族)为21-羟化酶缺陷非经典型肾上腺增生。
  • 较少见病因包括雄激素分泌性肿瘤、医源性/药物性、肢端肥大症、库欣综合征、严重胰岛素抵抗/脂肪营养不良综合征、卵巢卵泡膜细胞增生症和慢性皮肤刺激。

关键数值与推荐

  • 多毛症通常定义为mFG评分大于4~6,具体诊断阈值随种族略有差异。
  • 多毛症女性中多囊卵巢综合征占80%~90%,特发性多毛占5%~10%,21-羟化酶缺陷非经典型肾上腺增生占1%~10%(取决于种族)。

临床怎么用

  • 治疗选择取决于症状严重度、患者生育目标和潜在病因。
  • 管理选项包括药物治疗(如复方口服避孕药和抗雄激素药物)与物理脱毛方法。
  • 最有效治疗策略为上述方式联合,共享决策为关键驱动。
  • 临床医生不应低估多毛症所致患者痛苦程度。
  • 因多毛主诉就诊的女性无论体检可见程度如何均应评估潜在病因。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hirsutism affects approximately 10% of women globally, with substantial economic and quality of life effect. Facial and body terminal hair growth in a male-like pattern is determined by a number of factors, including circulating androgens, and tissue androgen receptor, 5α-reductase, 3α- and 17β-hydroxysteroid dehydrogenase, and ornithine decarboxylase content. The presence of hirsutism is usually determined by the modified Ferriman-Gallwey (mFG) visual scale, assessing the amount of terminal hair at 9 body sites (upper lip, chin, chest, upper and lower back, upper and lower abdomen, upper arms, and thighs). Specific diagnostic cutoffs vary somewhat by ethnicity, although hirsutism is usually defined by an mFG score greater than 4 to 6. Hirsutism is a sign of polycystic ovary syndrome in 80% to 90% of affected women, idiopathic hirsutism in 5% to 10%, and, depending on ethnicity, 21-hydroxylase-deficient nonclassic adrenal hyperplasia in 1% to 10%. Rarer causes include androgen-secreting neoplasms, iatrogenic/drug-induced, acromegaly, Cushing syndrome, syndromes of severe insulin resistance/lipodystrophy, ovarian hyperthecosis, and chronic skin irritation. The choice of treatment for hirsutism depends on the severity of symptoms, the patient's reproductive goals, and the underlying cause. Clinicians should not underestimate the degree of patient distress caused by hirsutism. Further, women who complain of excess unwanted hair growth should be evaluated for underlying causes, regardless of the degree to which hirsutism is observable on examination. Management options include medical therapies, such as combined oral contraceptive pills and antiandrogens, and mechanical methods of hair removal. The most effective therapeutic strategy will involve a combination of these modalities, with shared decision-making a key driver.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Azziz R, Amiri M, Bril F, et al. Approach to the Patient: Hirsutism. J Clin Endocrinol Metab. 2025. PMID: 40200552. doi:10.1210/clinem/dgaf226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。